A crucial step in internationalization strategy has been achieved. Recently, AB&B BIO-TECH-B (02627) successfully delivered its self-developed quadrivalent influenza subunit vaccine, "HuiErKangXin," to the Macau Special Administrative Region, completing customs clearance and marking its first export to Macau. This milestone not only signifies international recognition of the company's R&D capabilities and production quality but also represents a key achievement in its global expansion.

The quadrivalent influenza subunit vaccine supplied to Macau utilizes advanced third-generation flu vaccine technology, incorporating two influenza A and two influenza B virus surface antigens. It boasts high purity, excellent safety, and strong immunogenicity. Compared to traditional vaccines, this product features optimized manufacturing processes, significantly improving vaccination safety and protective efficacy, making it suitable for diverse populations, including high-risk groups.

With the current flu season underway, Macau has been reinforcing its prevention measures against respiratory infectious diseases. The timely introduction of this vaccine will provide Macau residents with a high-quality, reliable immunization option, strengthening the region's public health defenses.

**First Vaccination Ceremony Held, Promoting a Healthier Macau** On December 4, the inaugural vaccination ceremony took place at Macau's YinKui Hospital. The event highlighted the importance of proactive health management and preventive care, aligning with the company's vision: "Bringing global innovative vaccines to China and high-quality Chinese vaccines to the world."

The company's overseas business director stated, "We are honored to introduce this advanced subunit influenza vaccine to our compatriots in Macau. This collaboration is not just a market expansion breakthrough but also a significant step toward realizing our vision of delivering China's premium vaccines worldwide. We remain committed to supporting Macau's public health initiatives and safeguarding the well-being of its residents."

**Continuous Innovation for a Broader Global Stage** The successful delivery and deployment of the vaccine in Macau exemplify the steady progress of the company's internationalization strategy. To date, the company has established partnerships with multiple countries and regions. Moving forward, it will continue to drive innovation, expand its vaccine pipeline, and bring more high-quality products to global markets, contributing to a shared global health community.

This collaboration has provided valuable experience for the company in deepening its presence in the Guangdong-Hong Kong-Macau Greater Bay Area and expanding international channels, while also offering a reliable Chinese solution for global influenza prevention and control.